Skip to main content

Vijoice

Pronunciation: vii-joiz
Generic name: alpelisib
Dosage form: oral tablets, oral granules
Drug class: PI3K inhibitors

Medically reviewed by Judith Stewart, BPharm. Last updated on Apr 29, 2024.

What is Vijoice?

Vijoice (alpelisib) is an oral kinase inhibitor that may be used to treat severe phosphatidylinositol-3-kinase catalytic subunit alpha (PIK3CA)-Related Overgrowth Spectrum (PROS) in adults and children aged 2 years and older. It is taken once a day.

PROS is a spectrum of rare conditions characterized by abnormal overgrowth and structural abnormalities in blood vessels, the lymphatic system, and other tissues.

Vijoice works by inhibiting the PI3K pathway, one of the most important intracellular pathways involved in cell proliferation, cell regulation, and cell death. Mutations in this pathway have been found to cause a range of overgrowth and malformations that comprise the range of disorders commonly known as PROS. 

Vijoice was approved on April 6, 2022, under an accelerated approval designation. Continued approval may be subject to favorable results from further clinical trials.

Who should not take Vijoice?

You should not take Vijoice if you have had a severe allergic reaction to alpelisib or are allergic to any of the ingredients.

It is not known if this medicine is safe and effective in children below 2 years of age.

Before you take Vijoice

Before you start treatment, tell your healthcare provider about all of your medical conditions, including if you:

Males with female partners who are able to become pregnant should use condoms and effective birth control during treatment, and for 1 week after the last dose. If your female partner becomes pregnant, tell your healthcare provider right away.

What other drugs will affect Vijoice?

Tell your healthcare provider about all of the medicines you take, including prescription and over-the-counter medicines, vitamins, and herbal supplements. Vijoice and other medicines may affect each other causing side effects. Know the medicines you take. Keep a list of them to show your healthcare provider or pharmacist when you get
a new medicine.

How should I take Vijoice?

Vijoice tablets

Vijoice oral granules

Each packet is for single use only. Do not use the packet if the packet seal is broken.

Open the packet of Vijoice oral granules by holding them with the cut line on top.

Vijoice oral granules may be taken in one of the following ways:

Dosing information

Usual Adult Dosage for PIK3CA-Related Overgrowth Spectrum

Usual Pediatric Dosage for PIK3CA-Related Overgrowth Spectrum

Vijoice side effects

Vijoice may cause serious side effects, including:

Your healthcare provider may tell you to decrease your dose, temporarily stop your treatment, or completely stop your treatment if you get certain serious side effects.

The most common side effects affecting 10% or more people include:

Vijoice may affect fertility in males and in females who can become pregnant. Talk to your healthcare provider if this is a concern for you. These are not all of the possible side effects. Call your doctor for medical advice about side effects. You may report side effects to the FDA at 1-800-FDA-1088.

How should I store Vijoice?

Keep all medicines out of the reach of children and pets.

What are the ingredients in Vijoice?

Vijoice tablets

Active ingredient: alpelisib
Inactive ingredients: hypromellose, magnesium stearate, mannitol, microcrystalline cellulose, and sodium starch glycolate.

The film-coating contains hypromellose, iron oxide red (applicable only to 50 mg and 200 mg strengths), iron oxide yellow, macrogol/polyethylene glycol (PEG) 4000, talc, and titanium dioxide.

Vijoice oral granules

Active ingredient: alpelisib
Inactive ingredients: hypromellose, magnesium stearate, mannitol, microcrystalline cellulose, and sodium starch glycolate.

Manufacturer

Novartis Pharmaceuticals Corporation.

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.